Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2018 | Clinical trial data for TKIs in ALK-rearranged NSCLC

Silvia Novello • 11 Apr 2018
ELCC 2018
Lung Cancer Non-Small Cell Lung Cancer Alectinib Ceritinib
ALEX ASCEND-4 PROFILE 1014

Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses results from recent clinical trials exploring the efficacy of different tyrosine kinase inhibitors (TKIs) on ALK-rearranged non-small cell lung cancer (NSCLC) at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.

More from Silvia Novello

1:17
The reality of implementing TKI therapies for NSCLC in Europe
Silvia Novello • 11 Apr 2018
1:23
Optimizing treatment of ALK+ NSCLC: clinical realities
Silvia Novello • 11 Apr 2018
0:57
Goals for precision medicine in NSCLC
Silvia Novello • 11 Apr 2018
2:23
Exciting results from the ALEX trial
Silvia Novello • 8 Sep 2017

Related Videos

3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals